Amgen 2009 Annual Report Download - page 2

Serving Patients for 30 Years
Since 1980, Amgen has been a pioneer, leader, and innovator in medical biotechnology. Amgen medicines have helped more
than 18 million people around the world fi ght cancer, kidney disease, rheumatoid arthritis, and other serious illnesses.
With a number of novel potential new medicines in our pipeline, the next decade will mark a promising new chapter for Amgen—
and for patients. We are conducting medical research and clinical trials in our current therapeutic areas, and branching out
into new areas where fresh treatment approaches are urgently needed—areas such as bone health, cardiovascular disease,
cholesterol management, diabetes, and asthma. These are persistent and diffi cult medical issues that seriously impact the lives
of growing numbers of patients around the globe.
Biotechnology medicine plays an ever greater role in improving the lives of people everywhere, and Amgen continues to lead the
charge, in our own research laboratories and manufacturing facilities and in partnership with the industry’s foremost innovators
worldwide. Wherever biomedical innovation is happening and wherever patients need us most, that’s where Amgen will be.
Serving Patients
“Both my mother and sister also had
osteoporosis, and they suffered with
hunched backs and broken bones.
I realize that I have the power to help
keep my bones strong. I go to the
gym regularly, eat well, and visit my
doctor. I want to do all I can to stay
independent.” —Louise, denosumab
clinical trial participant
Above: Louise walks in a park near
her home in Gaithersburg, Maryland.
Driving Innovation
Amgen, the world’s leading biotechnology
medicines company, is among a select
few biotechs that are fully integrated—
combining innovative laboratory research
and clinical development with world-class
manufacturing and distribution capabilities.
Above: An Amgen staff member in a
research laboratory at the company’s
headquarters in Thousand Oaks,
California.
Fighting Serious Illness
Research and development at Amgen
begins with science and ends with
new therapies with the potential to help
millions. Our strong, emerging pipeline
contains novel approaches for treating
diabetes, asthma, heart disease, skeletal
problems, and high cholesterol, among
other diseases and conditions.
Above: Cardiac muscle cells showing
the cardiac sarcomere, the fundamental
contractile element of the heart, the
target of an investigational therapy for
heart failure that Amgen is developing
with Cytokinetics.
Researching New Frontiers
Amgen fi ghts cancer on multiple fronts
by exploring numerous biologic pathways
that play a role in cancer’s growth and
survival. One of many areas of study
that Amgen scientists are taking in
new directions is angiogenesis—the
process by which tumors induce new
blood vessel growth.
Above: A multimedia website,
angiogenesis.amgen.com, brings
to life the angiogenesis process
and the novel approaches being
taken by Amgen researchers.